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Abstract. 
 
We used expression proﬁling to deﬁne the
pathophysiological cascades involved in the progres-
sion of two muscular dystrophies with known primary
biochemical defects, dystrophin deﬁciency (Duchenne
muscular dystrophy) and 
 
a
 
-sarcoglycan deﬁciency (a
dystrophin-associated protein). We employed a novel
protocol for expression proﬁling in human tissues using
mixed samples of multiple patients and iterative com-
parisons of duplicate datasets. We found evidence for
both incomplete differentiation of patient muscle, and
for dedifferentiation of myoﬁbers to alternative lin-
eages with advancing age. One developmentally regu-
lated gene characterized in detail, 
 
a
 
-cardiac actin,
showed abnormal persistent expression after birth in
60% of Duchenne dystrophy myoﬁbers. The majority of
 
myoﬁbers (
 
z
 
80%) remained strongly positive for this
protein throughout the course of the disease. Other de-
velopmentally regulated genes that showed widespread
overexpression in these muscular dystrophies included
embryonic myosin heavy chain, versican, acetylcholine
receptor 
 
a
 
-1, secreted protein, acidic and rich in cys-
teine/osteonectin, and thrombospondin 4. We hypothe-
 
size that the abnormal Ca
 
2
 
1
 
 inﬂux in dystrophin- and
 
a
 
-sarcoglycan–deﬁcient myoﬁbers leads to altered de-
velopmental programming of developing and regener-
ating myoﬁbers. The ﬁnding of upregulation of HLA-
DR and factor XIIIa led to the novel identiﬁcation of
activated dendritic cell inﬁltration in dystrophic muscle;
these cells mediate immune responses and likely induce
microenvironmental changes in muscle. We also docu-
ment a general metabolic crisis in dystrophic muscle,
with large scale downregulation of nuclear-encoded mi-
tochondrial gene expression. Finally, our expression
proﬁling results show that primary genetic defects can
be identiﬁed by a reduction in the corresponding RNA.
Key words: muscular dystrophy • microarray • dys-
trophin • 
 
a
 
-sarcoglycan • expression proﬁling
 
Introduction
 
The dystrophin–glycoprotein complex of muscle fibers has
emerged as a critical multiprotein complex that imparts
structural integrity to the muscle fiber plasma membrane
during the contraction of skeletal muscle. Identification of a
principle component, dystrophin (Hoffman et al., 1987a),
led to the identification of additional protein components of
the protein complex (Ibraghimov-Beskrovnaya et al., 1992;
Roberds et al., 1993; Bonnemann et al., 1995; Noguchi et al.,
1995; McNally et al., 1996; Nigro et al., 1996). A major role
of these proteins is to provide physical connections between
intracellular cytoskeletons (actin filaments) and extracellu-
lar basal lamina (laminins). In brief, dystrophin attaches
to the plasma membrane via the transmembrane protein
 
b
 
-dystroglycan using a cysteine-rich COOH-terminal do-
main. Physical connections between the plasma membrane
and basal lamina are mediated by a multimeric chain involv-
ing dystrophin, 
 
b
 
-dystroglycan, 
 
a
 
-dystroglycan, and laminin
 
a
 
-2. The interaction of dystrophin with 
 
b
 
-dystroglycan is
stabilized by the heterotetrameric sarcoglycan complex (
 
a
 
,
 
b
 
, 
 
d
 
, and 
 
g
 
 subunits) (Ervasti and Campbell, 1991; Cullen et
al., 1996; Duclos et al., 1998). Interactions between dystro-
phin and intracellular actin filaments is mediated by a series
of actin-binding sites, many of which are clustered in the
NH
 
2
 
-terminal 200 amino acids. Importantly, loss of dystro-
phin leads to loss of all actin–filament association with the
plasma membrane (Rybakova et al., 2000). Utrophin is a
paralogue of dystrophin, which can in part functionally re-
 
place dystrophin when overexpressed in muscle,
 
 
 
though it is
not able to restore actin–filament association with the mem-
brane
 
 
 
(Tinsley et al., 1998; Rybakova et al., 2000). The dys-
trophin/dystroglycan/laminin complex is partially redun-
dant with the vinculin/integrin/laminin complex, though the
dystrophin-based complex seems more important for ho-
meostasis during muscle contraction, whereas the integrin-
based cytoskeleton appears more important for the appro-
priate development of muscle (Hayashi et al., 1998; Burkin
and Kaufman, 1999; Kaariainen et al., 2000).
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In addition to the structural role for dystrophin and the
associated proteins, there is clear evidence for signal trans-
duction roles. The COOH-terminal domains of dystrophin
bind a series of proteins, both directly and indirectly, each
of which has been shown to have a role in muscle develop-
ment or homeostasis. The dystrophin-binding syntrophins
are a series of proteins with PDZ domains that in turn
bind nNOS, ERK6, and other proteins (Yang et al., 1995;
Chao et al., 1996; Hasegawa et al., 1999). Loss of dystro-
phin leads to the secondary loss of nNOS at the plasma
membrane and defects in local blood flow regulation dur-
ing exercise (Thomas et al., 1998). There are likely many
additional directly or indirectly interacting proteins in-
volved in signal transduction, and the delineation of these
pathways is critical for understanding the pathophysiology
of dystrophin deficiency.
Genetic abnormalities of dystrophin are the cause of the
most common type of muscular dystrophies, Duchenne
and Becker muscular dystrophy. The gene encoding dys-
trophin has a very high mutation rate (1 in 10,000 germline
cells), due to the large size of the gene (2.5 million bp) and
the presence of certain hotspots for rearrangements within
introns (Gorospe and Hoffman, 1992; Hamed et al., 2001).
As a result, the disease has a high incidence in all world
populations, as well as in animals (Williams et al., 1983;
Bulfield et al., 1984; Cooper et al., 1988; Carpenter et al.,
1989; Roddie and Bundey, 1992). The presentation and
progression of dystrophin deficiency varies dramatically
between species, despite the shared biochemical feature of
complete deficiency of the protein in muscle and heart
from fetal life onward. Humans show evidence of myofiber
membrane instability (high serum creatine kinase levels)
from birth onwards, but do not show obvious clinical weak-
ness until 
 
z
 
4 yr of age. The disease is then progressive,
with patients gradually losing most of their skeletal muscle
by 16 yr of age (Hoffman and Schwartz, 1991). Cats and
mice lacking dystrophin show muscle hypertrophy as the
predominant symptom, with little clinical evidence of
weakness or muscle loss (Bulfield et al., 1984; Carpenter et
al., 1989; Gaschen et al., 1992). Dogs lacking dystrophin
show an even more rapid onset and progression than hu-
mans, though this can be variable from dog to dog (Cooper
et al., 1988; Kornegay et al., 1988). Primary deficiencies of
each of the sarcoglycan proteins have been documented in
human patients, and the clinical symptoms are indistin-
guishable from primary dystrophinopathies (Duggan et al.,
1997). Rodent models have been described for each of the
four sarcoglycans, and, like dystrophin deficiency, these
mouse and hamster models show muscle hypertrophy as
the primary clinical symptom (Mizuno et al., 1995; Duclos
et al., 1998; Hack et al., 1998; Durbeej et al., 2000).
The dramatic progressive nature of dystrophin defi-
ciency and sarcoglycan deficiency in humans and dogs, but
not cats and rodents, implies that there are important sec-
ondary, downstream effectors of muscle wasting and weak-
ness. The clinical differences between the human diseases
and their animal orthologues also support this hypothesis.
Considerable data has recently accumulated concerning
biochemical and environmental effectors of “acute” myofi-
ber damage and necrosis, particularly in regards to mem-
brane damage (plasma membrane fragility) and functional
ischemia (nNOS deficiency) (Thomas et al., 1998). These
“acute” features appear to be shared between dystrophin
and 
 
a
 
-sarcoglycan–deficient fibers of all species. Less well
studied are the secondary “chronic” aspects of these disor-
ders, which is particularly important as the downstream
events appear responsible for the progressive weakness
and early death in human patients. Histopathological cor-
relations have provided descriptive associations with the
progressive aspects of the human disease, such as prolifera-
tion of connective tissue (fibrosis), failure of myofiber re-
generation, and infiltration of mast cells and other inflam-
matory cells (Hoffman and Schwartz, 1991; Gorospe et al.,
1994a). However, no clear pathophysiological cascades
have yet been defined and no molecular basis identified for
any of the histological correlates.
We hypothesized that genome-wide expression profiling
would provide insight into the downstream pathophysio-
logical cascades in the muscular dystrophies. We felt that
the muscular dystrophies would be an excellent disease
system in which to apply emerging microarray technology
for the following reasons. First, muscle is a relatively sim-
ple tissue, with the myofiber being the predominant cell
type. Second, muscle is routinely biopsied from human pa-
tients and rapidly frozen, making tissue easily available for
expression array studies. Third, the primary molecular de-
fect in many cases of muscular dystrophy is known, such
that it is possible to study groups of genetically homoge-
neous patients. To test this, we present expression profil-
ing using Affymetrix HuGeneFL high-density oligonucle-
otide arrays (
 
z
 
6,000 full-length genes) on human muscle
biopsies from dystrophin deficiency, 
 
a
 
-sarcoglycan defi-
ciency (
 
a
 
-SGD),
 
1
 
 and normal controls.
 
Materials and Methods
 
Patient Materials
 
We used muscle biopsies from primary dystrophinopathy (Duchenne
muscular dystrophy [DMD] and female manifesting carriers), other dys-
trophies (
 
a
 
-SGD, calpain deficiency, and merosin deficiency), and normal
controls. All patients had documented mutations of the corresponding
genes (
 
a
 
-sarcoglycan, merosin, and calpain III; see below) or showed pri-
mary biochemical deficiency at the protein level (dystrophinopathies:
DMD, and female manifesting carriers).
For expression profiling, frozen muscle biopsies from five male patients
with dystrophin deficiency (age 6–9 yr), four patients with 
 
a
 
-SGD (two
males and two females; age 8–11 yr), and five male controls (age 6–9 yr)
were used. For dystrophin deficiency, all biopsies were shown to have
marked dystrophin deficiency by immunoflouresence (60 kD and d10
polyclonal antibodies [Hoffman et al., 1987b; Koenig et al., 1988] and/or
dys III COOH-terminal antibody monoclonal antibodies [Novocastro]
[Nicholson et al., 1989]), immunoblot (30 kD [Hoffman et al., 1987b] or
dys II rod domain [Novocastro] [Nicholson et al., 1989]), or both. All pa-
tients showed clinical symptoms consistent with the diagnosis of DMD.
All patients showed a dystrophic myopathy by hematoxylin/eosin staining
and dramatic elevations of serum creatine kinase level. For 
 
a
 
-SGD, all bi-
opsies were shown to have normal dystrophin by immunostaining and im-
munoblot, but complete 
 
a
 
-SGD by immunostaining. Patients used for ex-
pression array experiments had the following previously reported gene
mutations in the 
 
a
 
-sarcoglycan gene: I103T/L173P compound heterozy-
gote, I124T, where the second allele was not expressed at the RNA level,
R77C/D97G compound heterozygote, and 
 
D
 
C166 homozygote (Duggan
 
1
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a
 
-SGD, 
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-sarcoglycan deficiency; C3,
complement component 3; DMD, Duchenne muscular dystrophy;
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cysteine. 
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et al., 1997). All patients showed a dystrophic myopathy by hematoxylin/
eosin staining and elevation of serum creatine kinase levels. Control biop-
sies were from patients sent for diagnosis of a possible myopathy, but who
showed normal muscle histology by hematoxylin/eosin staining, normal
myofiber structure by electron microscopy, and normal mitochondria en-
zyme activity.
For immunostaining experiments, muscle biopsies from normal con-
trols (7 males and 1 female; age fetus to 26 yr), DMD (17 males; age fetus
to 9 yr), 
 
a
 
-SGD (2 females, age 8 and 12 yr), female-manifesting carriers
of Duchenne dystrophy (mosaic for dystrophin) (2 females, age 4 and 7
yr), calpain III deficiency (female, 15 yr), and partial-merosin deficiency
(female, 23 yr) were studied. 
 
a
 
-Sarcoglycan patients used for immu-
nostaining had the following mutations: compound heterozygote I103T/
L173P, and compound heterozygote R77C/A93V (Duggan et al., 1997).
For calpain III deficiency and partial-merosin deficiency, biopsies were
shown to have normal dystrophin by immunofluorecence and immuno-
blot. The partial-merosin deficient patient showed partial-merosin defi-
ciency, by immunofluorecence, and a C862R missense mutation, with the
second allele not expressed at the RNA level (Tezak et al., 2000). The
calpain III–deficient patient showed a R572Q homozygous/hemizygous
mutation in the calpain III gene as previously reported (Chou et al., 1999).
 
Expression Profiling
 
Five dystrophin deficient, four 
 
a
 
-sarcoglycan deficient, and five control
muscle biopsies were used to extract total RNA by using TRI
 
ZOL
®
 
 reagent
(GIBCO BRL). Each biopsy was divided into two fragments, and RNA
was isolated from each fragment independently (28 biopsy fragments to-
tal). 10
 
 m
 
g of total RNA from each biopsy fragment (28 muscles total) was
converted into double-stranded cDNA by using SuperScript Choice sys-
tem (GIBCO BRL) with an oligo-dT primer containing T7 RNA poly-
merase promoter (Genset). The double-stranded cDNA was purified by
phenol/chloroform extraction, and then used for in vitro transcription us-
ing ENZO BioArray RNA transcript labeling kit (Affymetrix). Biotin-
labeled cRNA was purified by RNeasy kit (QIAGEN), and fragmented
randomly to 
 
z
 
200 bp (200 mM Tris-acetate, pH 8.2, 500 mM KOAc, 150
mM MgOAc). cRNA samples of each group were pooled in duplicate be-
fore hybridizing to Affymetrix HuGeneFL microarray for 16 h. The mi-
croarray was washed and stained on the Affymetrix Fluidics Station 400,
using instructions and reagents provided by Affymetrix. This involves re-
moval of nonhybridized material, and then incubation with phycoeryth-
rin–streptavidin to detect bound cRNA. The signal intensity was ampli-
fied by second staining with biotin-labeled anti-streptavidin antibody and
followed phycoerythrin–streptavidin staining. Fluorescent images were
read using the Hewlett-Packard G2500A Gene Array Scanner.
 
Data Analysis
 
Data analysis of Affymetrix microarrays was done using GeneChip
 
®
 
 soft-
ware (version 3.3), as described previously (Lockhart et al., 1996). In brief,
each gene is queried by 20 perfect match (PM) and 20 mismatch (MM) 25-
base probes; the latter has a single base change in the center of the 25-bp
probe. Comparison of the hybridization signal from the PM and MM
probes allows a specificity measure of signal intensity, and elimination of
most nonspecific cross-hybridization from the data analysis. Values of in-
tensity difference, as well as ratios of each probe pair, are used for deter-
mining whether a gene is called “present” or “absent.” For comparison of
different datasets (e.g., dystrophin deficiency versus normal control), each
probe pair in an experimental GeneChip
 
®
 
 assay is compared with control
groups, and four matrixes were used to determine the difference calls that
indicate whether transcription level of a gene is changed.
Iterative comparisons of different datasets were done by spreadsheet
analysis (Microsoft Excel). In brief, each dystrophin deficiency chip (
 
n 
 
5
 
2) and 
 
a
 
-SGD chip (
 
n 
 
5
 
 2) was compared with each control chip (
 
n 
 
5
 
 2)
to determine the expression difference between each muscular dystrophy
and the control. Difference calls that showed consistent results in all four
pairwise comparisons of each disease were extracted for further analysis.
 
Immunohistochemistry
 
Polyclonal antibodies against complement component 3 (C3) and throm-
bospondin-4 were provided by Dr. Fernando Vivanco (Fundacion Jime-
nez Diaz, Madrid, Spain) (Alberti et al., 1996) and Dr. Jack Lawler (Beth
Israel Deaconess Medical Center and Harvard Medical School, Boston,
MA) (Lawler et al., 1995). Sheep-anti–human factor XIIIa polyclonal an-
tibody was from Cedarlane. Monoclonal antibody against HLA-DR was
 
from Biomeda. Monoclonal antibody against secreted phospholipase A2
was from Cayman Chemical. Monoclonal antibodies against secreted pro-
tein, acidic and rich in cysteine (SPARC)/osteonectin and versican were
from USBiological. A monoclonal antibody against 
 
a
 
-cardiac actin was
from Maine Biotechnology Services. All secondary antibodies were pur-
chased from Jackson ImmunoResearch Laboratories, including FITC-
conjugated donkey anti–mouse IgG, Cy3-conjugated goat anti–mouse
IgG, Cy3-conjugated donkey anti–sheep IgG, and Cy3 conjugated donkey
anti–rabbit IgG.
Serial 4-
 
m
 
m-thick frozen muscle sections were cut with an IEC Mino-
tome cryostat, mounted to Superfrost Plus Slides (Fisher Scientific,), and
fixed in cold anhydrous acetone. Sections were then blocked for 30 min in
10% horse serum and 1
 
3
 
 PBS, and incubated with primary antibody for
3 h at room temperature. Antibody dilutions were as follows: (a) 1:500 for
C3, thrombospondin-4, and factor XIIIa, (b) 1:200 for PLA2, (c) 1:10,000
for SPARC/osteonectin (d) 1:2,000 for versican, (e) 1:1,000 for embryonic
myosin heavy chain, (f) 1:20 for HLA-DR, and (g) 1:10 for 
 
a
 
-cardiac actin.
Washes were done with 10% horse serum and 1X PBS, and sections then
incubated with secondary antibody for 1 hour. FITC-conjugated donkey
anti-mouse IgG was diluted 1:100. All other Cy3-conjugated secondary
antibodies were diluted 1:500.
 
Online Supplemental Materials
 
Affymetrix image files for the six chip hybridizations and the absolute
analysis results of each chip are available at http://www.jcb.org/cgi/content/
full/151/6/1321/DC1.
 
Results
 
Expression Profiling of Dystrophin Deficiency
and 
 
a
 
-SGD
 
The goal of this study was to determine downstream gene
expression changes resulting from known primary bio-
chemical defects in muscle. However, other sources of
gene expression changes include variability in cell-type
content of patient muscle biopsies and genetic background
differences between individuals. These variables can com-
plicate interpretation. To minimize the effect of these vari-
Figure 1. Experimental protocol employed for expression array
analyses. 
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ables, we used the following experimental strategy (Fig. 1).
First, each patient muscle biopsy to be studied was split
and processed in duplicate. The duplication of each biopsy
sample would be expected to control for all sources of
both tissue and experimental variability, including cell-
type heterogeneity within the tissue, variables in RNA iso-
lation and biotinylated cRNA production, and variability
in hybridization to GeneChip
 
®
 
 microarrays. Second, to
 
minimize genetic polymorphic variation in expression pat-
terns between different individuals, we studied four or five
patient biopsies simultaneously, with equal amounts of
cRNA mixed for each of the groups, and the resulting
cRNA pools were then hybridized to a single GeneChip
 
®
 
array. Polymorphic variations in expression profiles should
be normalized by this approach, whereas gene expression
changes correlating with the primary biochemical defect
should be retained. The mixing protocol also reduced the
cost of the analysis, requiring substantially less microar-
rays to carry out the experiments. This protocol resulted in
six datasets (normal1, normal2, DMD1, DMD2, 
 
a
 
-SGD1,
and 
 
a
 
-SGD2) (Fig. 1). An example of raw image data
showing hybridization of cRNA to 20 probe pairs of a sin-
gle gene is shown in Fig. 2 A.
Description of genes tested on the GeneChip
 
®
 
 Hu-
GeneFL array is listed on our site (http://www.cnmcre-
search.org; link to microarray). Among the 7,095 probe sets
(
 
z
 
280,000 oligonucleotide features) on the Affymetrix Hu-
GeneFL microarray, we found a consistent number of
“present” calls for each of the six cRNA pools tested (con-
trol 32 and 37%; DMD 36 and 32%; 
 
a
 
-SGD 30 and 36%).
Data from each experiment is posted on a web site for pub-
lic access, and comparison to other HuGeneFL datasets
(http://microarray.CNMCResearch.org/resources.htm; link
to “muscle, human”). Included on the web site is the raw im-
Figure 2. Expression profile data for pooled muscular dystrophy
patient biopsies. (A) Example of raw data of probe sets for ERK6
in normal pooled controls (Control 1), DMD (DMD1), and a-sar-
coglycan–deficient (a-SGD1) patient biopsies. Shown are 20
probe pairs for the ERK6 gene on the GeneChip® HuGeneFL ar-
ray, with the top feature of each pair showing hybridization of
RNA to the perfect match probe (PM), and the lower feature
showing the mismatched control probe (MM). Relative quantita-
tion of averaged features is provided, as well as the difference call
(e.g., increase or decrease) comparing DMD1 and a-SGD1 to the
control 1 dataset. This analysis shows a 10-fold reduction of
ERK6 mRNA specific for DMD. Probe pairs whose performance
is inconsistent with the rest of probe set are indicated, with one
showing equal hybridization with match and mismatch (#), one
showing likely cross-reactivity to a more abundant RNA se-
quence (*), and one showing lack of hybridization (1). The color
bar indicates intensity ranged from 500 to 20,000. (B) Scatter
graph representation of comparative data, with axes showing rel-
ative expression levels of probe sets for each gene. Shown are sin-
gle comparisons of expression profiling data sets (DMD1 versus
DMD2; Control 1 versus DMD1). Lack of concordance between
DMD1 and DMD2 represents combined experimental error, in-
cluding tissue heterogeneity in muscle biopsy. Only “present”
calls are shown, which represent z2,000 of the 6,000 genes tested.
Comparison of control 1 and DMD1 data sets shows considerably
more spread in expression levels throughout the intensity range,
indicating gene expression relevant to dystrophin deficiency in
muscle. The solid lines indicate twofold difference cutoff.
Figure 3. Iterative comparisons of duplicate data sets result in
stringent determination of differentially expressed genes. (A) The
effect of sequential iterative comparisons between DMD and con-
trol gene expression profiles is shown. A single data set compari-
son shows z250 increase and 250 decrease calls. Iterative compar-
isons of two independent data sets result in a decreasing number
of difference calls that survive all comparisons (158 increase and
155 decrease calls after two comparisons; 137 increase and 135 de-
crease calls after four comparisons). (B) The same iterative analy-
sis of a-sarcoglycan–deficient muscle versus normal controls is
shown. A similar decline in surviving difference calls is seen. 
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age files for each of the six microarrays, text files containing
absolute analyses of each chip (“present” calls; GeneChip
 
®
 
software output), and comparison analyses between differ-
ent chips (difference calls; GeneChip
 
®
 
 software output).
There was high concordance (88%) of “present” calls
between duplicated datasets. However, the level of RNA
found for each gene showed some variability between
datasets; consistent with most microarray data published
to date, the highest variability in levels was in genes show-
ing low levels of cRNA hybridization (Fig. 2 B). The vari-
ability in levels of specific genes is likely a combination of
tissue variability and experimental variability.
Genes that are consistently increased or decreased in all
four possible iterative comparisons were determined (e.g.,
control 1 versus DMD1, control 1 versus DMD2, control 2
versus DMD1, and control 2 versus DMD2) (Fig. 3). Only
 
z
 
40–60% of difference calls from a single comparison typ-
ically survived all four iterative comparisons of datasets.
For this analysis, “marginal” difference calls assigned by
GeneChip
 
®
 
 software analysis were retained in the data
sets. The cutoff used for difference calls was a twofold
change in expression (either increase or decrease). The
four iterative comparisons gave four values for “fold
change,” which were then averaged.
It is important to note that we focused on difference calls
that satisfied all four iterative comparisons of data. This can
be considered a very stringent selection of data, as genes
that showed significant changes in expression in three data
comparisons, but not the fourth, would be excluded from
further study. We studied a series of genes that showed dif-
ference calls in three comparisons, but not the fourth; in
each case the fold changes were close to the twofold cutoff
used (data not shown). All data is presented on the web site,
with selected data presented in Tables I and II.
From the four pairwise comparisons for each disease to
normal controls, we identified 275 differentially regulated
genes for dystrophin deficiency, and 233 differentially reg-
ulated genes for 
 
a
 
-SGD. Thus, 
 
z
 
30% of probe sets tested
were expressed in muscle, and 
 
z
 
10% of these showed dif-
ferential regulation in dystrophin deficiency and/or 
 
a
 
-SG
deficiency. Expression of 138 genes was upregulated, and
137 genes downregulated in dystrophin deficiency versus
control, 90 were upregulated and 143 genes downregu-
lated in 
 
a
 
-SGD versus control (Fig. 3). These data are also
presented as a log scale graph of fold changes, with and
without “tilda” values (Fig. 4). As explained in the figure
legend, “tildas” are assigned when the denominator ap-
proaches zero (e.g., “absent” call), leading to possible ex-
aggeration of the resulting ratio (Fig. 4).
 
Gene Expression Changes Shared by Dystrophin 
Deficiency and 
 
a
 
-SGD
 
We expected many pathological processes to be involved
in muscular dystrophy patient muscle, including degenera-
tion cascades, regeneration programs, and fibrotic prolif-
eration genes. We expected these changes to be shared be-
tween the two closely related primary biochemical defects.
Consistent with this, we found 144 genes to show greater
than twofold up and downregulation in both dystrophin
deficiency and 
 
a
 
-SGD. We then clustered these genes by
pathological processes (Table I). The largest functional
group of upregulated genes were genes of cell surface and
Figure 4. Comparison of differentially expressed genes in dys-
trophin deficiency and a-SGD expressed as fold changes com-
pared with normal muscle. Both graphs show average fold
changes  .2 on a log scale. Those spots on the diagonal repre-
sent genes that show a similar expression change in both dystro-
phin deficiency and a-SGD, whereas those lying off the hori-
zontal show greater differences in one or the other dystrophy.
(A) The graph includes all difference calls that included one or
more tilda values (z). This includes difference values where the
expression level in any single dataset approaches the noise
level, leading to an absent or marginal call. This often leads to a
very large value for the ratio (e.g., dividing by zero) for deter-
mination of fold change, with a resulting exaggeration of the
difference, and a higher probability of lying off the diagonal.
Many of these tilda genes are those that show little or no ex-
pression in normal muscle, and are increased in the muscular
dystrophies. (B) The graph shows removal of all data showing
tildas. These genes have a strong confidence level with regards
to the extent of the difference with normal muscle, and also the
relative difference with regards to the two muscular dystro-
phies. Of particular note is the disease-specific decrease of
ERK6 in dystrophin deficiency, and the very large increases in
many developmentally regulated muscle genes that are shared
by both muscular dystrophies. 
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(continues)
 
Table I. List of Shared Expression Changes of Genes in Dystrophin Deficiency and 
 
a
 
-SGD
 
Average-fold changes
Accession no. Gene name
Dystrophin 
deficiency
 
a
 
-Sarcoglycan 
deficiency
 
Cell surface and extracellular matrix
S77094 Nicotinic acetylcholine receptor 
 
a
 
 subunit 1 19 17
Z19585 Thrombospondin-4 15 23
HG2994-HT4850 Elastin, alt. splice 2 13 12
Z74616 Prepro-
 
a
 
2(I) collagen 11 7
U24488 Tenascin-X 11 7
U16306 Chondroitin sulfate proteoglycan versican 8 8
X53331 Matrix Gla protein 7 4
X52022 Type VI collagen 
 
a
 
3 chain 7 5
HG3044-HT3742 Fibronectin, alt. splice 1 6 6
M55998
 
a
 
-1 Collagen type I 6 5
J03040 SPARC/osteonectin 5 4
X15880 Collagen VI 
 
a
 
-1 COOH-terminal globular domain 5 7
U21128 Lumican 5 5
X02761 Fibronectin (FN precursor) 1 4 3
Z74615 Prepro-
 
a
 
1(I) collagen 3 3
L02950
 
m
 
-Crystallin
 
2
 
22
 
2
 
9
Intracellular signaling and cell–cell communication
M38591 S100 calcium-binding protein A10 5 6
M62403 Insulin-like growth factor–binding protein 4 (IGFBP4) 5 4
D13666 Osteoblast-specific factor 2 (OSF-2os) 4 7
M80563 S100 calcium-binding protein A4 4 5
HG2788-HT2896 Calcyclin 4 5
HG3543-HT3739 Insulin-like growth factor 2 3 3
U09578 MAPKAP kinase (3pK)
 
2
 
9
 
2
 
4
U50360 Calcium, calmodulin-dependent protein kinase II 
 
g2
 
9
 
2
 
12
L21993 Adenyl cyclase
 
2
 
6
 
2
 
3
U07225 P2U nucleotide receptor
 
2
 
5
 
2
 
6
M72885 G0S2
 
2
 
3
 
2
 
4
Immune response
M22430 Phospholipase A2, group IIA 42 21
X57351 1-8D gene from interferon-inducible gene family 37 30
K02765 Complement component C3, 
 
a and b subunits 22 11
X83703 Cytokine-inducible nuclear protein 8 16
M14058 Complement C1r 5 4
J04080 Complement component C1s 5 3
M65292 Factor H homologue 5 3
Energy metabolism and mitochondria function
HG4747-HT5195 NADH-ubiquinone oxidoreductase, 51 kD subunit 26 25
U65579 Mitochondrial NADH dehydrogenase-ubiquinone Fe-S protein 8 25 24
M69177 Monoamine oxidase B (MAOB) 25 27
J05073 Phosphoglycerate mutase (PGAM-M) 24 22
X66114 Solute carrer family 25,member 11 24 213
L77701 COX17 24 24
M37400 Glutamate oxaloacetate transaminase 24 24
X05409 Mitochondrial aldehyde dehydrogenase I ALDH I 24 23
M32598 Glycogen phosphorylase (PYGM) 23 22
J04444 Cytochrome c-1 23 23
X99728 NADH-ubiquinone oxidoreductase flavoprotein 3 23 22
X73874 Phosphorylase kinase,muscle,a1subunit 23 23
Z68204 Succinyl CoA synthetase 23 24
M91463 Glucose transporter (GLUT4) 23 24
S69232 Electron transfer flavoprotein-ubiquinone oxidoreductase 23 24
L16842 Cytochrome b of complex III 23 22
M22760 Cytochrome c oxidase subunit Va (COX5A) 22 22
M22632 Glutamate oxaloacetate transaminase 22 22
U80040 Aconitase 22 22
M15856 Lipoprotein lipase 22 25
L24774 D3, D2-CoA-isomerase 22 23
U49352 Liver 2,4-dienoyl-CoA reductase 1 22 25
M22877 Somatic cytochrome c (HCS) 22 22Chen et al. Expression Profiling in the Muscular Dystrophies 1327
extracellular proteins (42%). Additional functional groups
included genes involved in immune responses (20%) and
cell growth, differentiation, and signaling (15%).
Among 80 downregulated genes, 36% of them were in-
volved in mitochondria function and energy metabolism
(Table I). Importantly, this data suggests that there is a
widespread disorder of both aerobic and anaerobic energy
metabolism in patient muscle. Approximately 12% of
downregulated genes were involved in cell growth, differ-
entiation, and signaling. Specific genes were selected for
verification of expression changes by immunostaining of
patient muscle biopsies. As described below, all tested ex-
pression changes were confirmed by immunostaining data.
Gene Expression Changes Specific for Dystrophin 
Deficiency and a-SGD
We then tested for gene expression changes that were spe-
cific for either dystrophin deficiency or a-SG deficiency. We
expected that this analysis would provide valuable tran-
scriptional information regarding well documented second-
ary protein deficiencies in each disorder, and would help
determine whether these secondary biochemical abnormali-
ties were due to reduced RNA levels or protein instability.
In addition, we hypothesized that such disease-specific
changes might point to genes or proteins that could have a
functionally significant association with dystrophin or a-sar-
coglycan at the protein level or gene transcription level.
Such biochemical or genetic partners could provide insights
into novel pathways or pathophysiological cascades.
For dystrophin deficiency, 131 genes showed significant
expression changes relative to normal muscle, yet were as-
signed as “no change” in a-sarcoglycan deficient muscle.
Similarly, a-sarcoglycan deficient muscle showed 89 genes
with difference calls that were not seen in dystrophin defi-
ciency. However, the large majority of these genes, in both
dystrophin deficiency and a-SGD, showed relatively small
changes near the twofold cutoff for statistical acceptance
of a difference call. Thus, we felt it was likely that many, if
not most, of these potential disease-specific expression
Table I. (continued)
Average-fold changes
Accession no. Gene name
Dystrophin 
deficiency
a-Sarcoglycan 
deficiency
U17886 Succinate dehydrogenase complex subunit B 22 23
HG4334-HT4604 Glycogenin 22 22
Z14244 Cytochrome c oxidase subunit VIIb 22 22
Muscle structure and developmental genes
X13100 Embryonic myosin heavy chain 140 124
Z38133 Skeletal muscle perinatal myosin heavy chain (MYH8) 51 33
L05606 Myosin-binding protein H 32 51
J00073 a-cardiac actin 7 9
L03785 Regulatory myosin light chain (MYL5) 5 5
U34301 Nonmuscle myosin heavy chain IIB gene 3 4
S81737 a-1 Syntrophin 214 26
X06956 (probe set 1) a-Tubulin 211 27
HG2259-HT2348(probe set 2) a-Tubulin 28 26
L34355 a-Sarcoglycan 23 25
Others and unknown
M14539 Factor XIII subunit a 26 11
U51010 (probe set 1) Nicotinamide N-methyltransferase (NNMT) 22 17
U08021 (probe set 2) Nicotinamide N-methyltransferase (NNMT) 20 17
X68733 a1-Antichymotrypsin 6 4
M19045 Lysozyme 6 6
X14008 Lysozyme 5 5
X96719 Activation-induced C-type lectin (AICL) 3 4
X82209 Meningioma 1 29 28
L11672 Zinc finger protein 91 25 26
HG3344-HT3521 Ubiquitin-conjugating enzyme Ubch5 24 25
U03056 Tumor suppressor (LUCA-1) 24 25
M35252 Transmembrane 4 superfamily member 3 24 27
Y00339 Carbonic anhydrase II 24 24
Z49878 Guanidinoacetate N-methyltransferase 24 23
S83364 Putative Rab5-interacting protein 24 23
U52960 RNA polymerase II complex component SRB7 23 24
U48707 Protein phosphatase-1, regulatory subunit 8 23 24
U05861 Hepatic dihydrodiol dehydrogenase 23 23
U91903 Fritz 12 25
AB002365 KIAA0367 gene 9 19
U61374 Sushi-repeat–containing protein, X chromosome (SRPX) 7 5
X67698 Epididymal secretory protein (19.5 kD) 5 3
U79253 Clone 23893 27 28
D80010 KIAA0188 26 26
D14660 KIAA0104 24 24The Journal of Cell Biology, Volume 151, 2000 1328
changes represented experimental and biological “noise”
and not biochemical or genetic “partners” for dystrophin
or a-sarcoglycan.
To focus on those gene expression changes most likely
to represent biochemical or genetic “partners,” we se-
lected only those genes showing fivefold or greater
changes specifically for either dystrophin deficiency or
a-SGD (Table II). Using these criteria, only a relatively
few genes showed disease-specific changes in gene expres-
sion (12 upregulated and 4 downregulated genes specific
for dystrophin deficiency, and 11 upregulated and 9 down-
regulated genes specific for a-SGD).
Dystrophin-deficient patient biopsies showed a specific de-
crease in dystrophin mRNA (fourfold) that was not seen in
a-SGD, suggesting that primary genetic defects can poten-
tially be identified by expression profiling. However, there
were other genes showing similar or greater disease-specific
differences. Two disease-specific changes were an extracellu-
lar signal regulated kinase (ERK6; 10-fold decrease) and a
protein tyrosine phosphatase (8-fold decrease). For a-SGD,
nine genes showed disease-specific decreases. For example,
distinct sets of probes for the uncoupling protein3 gene de-
tected nine- and sevenfold decreases in a-sarcoglycan-defi-
cient, but not dystrophin-deficient patients.
Importantly, there were no significant gene expression
changes of well documented secondary protein deficiencies,
such as dystroglycan, sarcoglycans (b, d, and g), or nNOS.
Also, there was not a change in utrophin RNA levels in either
Duchenne or a-sarcoglycan dystrophies. On the other hand,
another dystrophin-binding protein, a1-syntrophin, showed
dramatic reductions in RNA levels in both dystrophin defi-
ciency (14-fold) and a-SGD (6-fold), and a-sarcoglycan
showed 3–5-fold reductions in both diseases as well.
A recent report has shown that ERK6 associates with
a1-syntrophin, and it is also known that the PDZ domain
of a1-syntrophin interacts directly the COOH terminus of
dystrophin (Hasegawa et al., 1999). Thus, some of the
biochemical partners of dystrophin (a1-syntrophin and
ERK6) are also seen to be part of a coordinately regulated
transcriptional group, as all three genes show dramatically
reduced levels of RNA. Our data suggests this coordi-
nately regulated gene cluster may also include a protein
tyrosine phosphatase as a similar disease-specific mRNA
reduction is seen.
Table II. List of Disease Specific Changes in Dystrophin Deficiency and a-SGD
Accession no. Gene name Average-fold changes
Dystrophin deficiency
U09579 Melanoma differentiation associated protein(mda-6) 16
J03909 g-Interferon–inducible protein (IP-30) 13
U32907 p37NB 12
U04285 Lysosomal acid lipase, cholesteryl ester hydrolase (LIPA) 9
Z37987(probe set 1) Glypican 3 (GPC3) 9
L47125(probe set 2) Glypican 3 (GPC3) 7
J03801 Lysozyme 6
L13391 Helix-loop-helix basic phosphoprotein (G0S8) 6
K03430 Complement C1q B-chain 6
X52947 Cardiac gap junction protein 5
X76534 NMB 5
L33799 Procollagen C-proteinase enhancer protein (PCOLCE) 5
X79483 ERK6 210
M64572 Protein tyrosine phosphatase 28
L37127 RNA polymerase II 27
U42031 54-kD progesterone receptor–associated immunophilin FKBP54 27
a-SGD
U16954 AF1q 26
X51441(probe set 1) Serum amyloid A (SAA) protein 18
J03474 Serum amyloid A 16
U20758 Osteopontin 13
M12529 Apolipoprotein E 13
X51441(probe set 2) Serum amyloid A (SAA) protein 10
X15882 Collagen VI a-2 6
M21119 Lysozyme 6
X63578 Parvalbumin 6
X78565 Tenascin-C 6
M34309 Epidermal growth factor receptor (HER3) 5
U80184 Nuclear aconitase mRNA, encoding mitochondrial protein 218
HG3141-HT3317 NADH-ubiquinone oxidoreductase, 39-kD subunit 213
X17644 GST1-Hs mRNA for GTP-binding protein 212
D25304 KIAA0006 211
AF001787 Uncoupling protein 3 29
X06956 HALPHA44 gene for a-tubulin 27
U82818 UCP3S 27
V01512 c-fos 26
D13635 KIAA0010 25Chen et al. Expression Profiling in the Muscular Dystrophies 1329
Confirmation of Gene Expression Changes, and 
Cellular Localization of Differentially Regulated 
Gene Products
To confirm our expression array findings, we chose a se-
ries of differentially regulated genes to study by immu-
nostaining patient muscle biopsies. This approach also al-
lowed us to identify the localization of the differentially
regulated gene product.
Serial 4-mm-thick frozen muscle sections were processed
for immunostaining with antibodies against 15 protein
products of differentially expressed genes. All were tested
on both unfixed and acetone-fixed sections of normal con-
trols, DMD, and a-sarcoglycan–deficient patient muscles.
A subset of antibodies were also tested on female mani-
festing carriers of DMD (somatic mosaic for dystrophin
expression in muscle) and unrelated muscular dystrophies
of known causes (calpain III deficiency and partial mero-
sin deficiency). Of the 15 antibodies tested, 9 provided ad-
equate signal/noise ratios for interpretation of protein lo-
calization and amount. Results of antibody studies are
summarized in Table III.
Factor XIIIa, HLA-DRa Heavy Chain. Factor XIIIa is a
protein known to be involved in blood coagulation as a fi-
brin cross-linker. We found upregulation of this gene by
11–26-fold in both muscular dystrophies, though the ex-
pression in normal muscle was undetectable by Gene-
Chip® array studies, hence possibly exaggerating the ex-
tent of upregulation. Immunolocalization of this protein
showed positive cells in both epimysial and endomysial
connective tissue in dystrophic muscle (Fig. 5). Double im-
munostaining with a marker for endothelium (laminin a1)
showed that the staining for factor XIIIa did not colocalize
with this protein, though the factor XIIIa–positive cells
were often in close proximity to blood vessels (data not
shown).
HLA-DR is a histocompatibility antigen highly expressed
in antigen presenting cells. HLA-DRa was upregulated in
both dystrophin-deficient (threefold) and a-sarcoglycan–
deficient (threefold) patient muscle. Immunostaining for
HLA-DRa showed strong immunolocalization to a subset
of cells that resembled those immunostained by factorXI-
IIa. Indeed, double immunostaining for both factor XIIIa
and HLA-DRa showed that most positively stained cells
coexpressed these two proteins (Fig. 5).
This data suggested that these cells represented tissue
dendritic cells (Sueki et al., 1993). To test this, immu-
nostaining was carried out with markers for circulating
dendritic cell subtypes (CD1a, CD1b, and CD1c). Many of
the factorXIIIa/HLADR-positive cells also stained with
CD1a, and less frequently with CD1b and CD1c (data not
shown). The data suggests that the infiltrating cells respon-
sible for expression of factorXIIIa and HLA-DRa are re-
lated to tissue (dermal) dendritic cells. This is the first re-
port of factor XIIIa1 and HLA-DR1 dendritic cell
infiltration in dystrophic muscles.
Thrombospondin 4, SPARC, and Versican.  Thrombo-
spondin 4 is an extracellular matrix calcium-binding pro-
tein particularly abundant in tendon and early osteogenic
tissues. It has been shown to be upregulated in denervated
muscle, though its function is poorly understood. Throm-
bospondin 4 was 15-fold increased in dystrophin defi-
ciency, and 23-fold increased in a-SGD. Immunostaining
of dystrophic patient muscle biopsies showed thrombo-
spondin 4 to be localized to areas of macrophage infiltra-
tion, though the areas showing very strong staining for
thrombospondin 4 extended beyond frankly necrotic re-
gions (Fig. 6, D–G). This data suggests that thrombospon-
din 4 is expressed by interstitial cells in response to mac-
rophage infiltration, denervation, and/or cellular damage
of neighboring myofibers (Arber and Caroni, 1995).
SPARC/osteonectin is an extracellular glycoprotein that
is strongly expressed during development and tissue re-
generation, where it functions to mediate connections be-
tween cells and the extracellular matrix (Lane and Sage,
1994). SPARC showed fivefold upregulation in dystrophin
deficiency, and fourfold elevation in a-SGD. Immunolo-
calization showed punctate immunostaining that was dra-
matically increased in the endomysial and perimysial con-
nective tissue (data not shown).
Versican is a chondroitin sulfate proteoglycan that, like
SPARC and thrombospondin, is prevalent in myogenesis
of muscle (Carrino et al., 1999). This gene showed eight-
fold upregulation in both dystrophies. Immunolocalization
identified diffusely increased amounts of the protein in en-
domysial, but not perimysial, connective tissue of dystro-
phic muscle (Fig. 6, A–C).
a-Cardiac Actin, Embryonic Myosin Heavy Chain. Both
a-cardiac actin and embryonic myosin heavy chain are
Table III. Gene Expression Changes Confirmed by Immunofluorescence
Gene name Accession no.
-fold change
DMD
-fold change
a-SGD
Normal muscle 
localization
Dystrophic muscle 
localization
Factor XIIIa M14539 126 111 None Cellular infiltrates
HLA-DR a heavy chain X00274 13 13 Small amount 
endomysium
Cellular infiltrates
Complement component 3 K02765 122 111 None Necrotic muscle fibers
Secreted phospholipase A2 M22430 142 121 None Necrotic muscle fibers
Thrombospondin-4 Z19585 115 123 Endomysium Focal increases
a-Cardiac actin J00073 17 19 None Majority of myofibers
Embryonic myosin heavy chain X13100 1141 1124 None Regenerating
muscle fibers
Osteonectin/SPARC J03040 15 14 Rare, punctate 
staining 
endomysium
Increase 
endomysium
Versican U16306 18 18 Endomysium
Diffuse increase
endomysiumThe Journal of Cell Biology, Volume 151, 2000 1330
specific isoforms of proteins that are transiently expressed
during normal muscle development and regeneration
(Whalen et al., 1979; Toyofuko et al., 1992). Both of these
proteins showed upregulation in dystrophic muscle: a-car-
diac actin was increased 7–9-fold and embryonic myosin
124–140-fold. Immunolocalization of these proteins in
muscle biopsies, similar to those used for expression pro-
filing, showed high-level expression of embryonic myosin
in z20% of dystrophic myofibers, and of a-cardiac actin in
z80% of fibers (Fig. 7).
Overt degeneration/regeneration of myofibers is a rela-
tively rare event by histological assays (Fig. 6), and the
large proportion of myofibers positive for these develop-
mentally specific isoforms did not seem to be justified by
the limited amount of regeneration in the dystrophic mus-
cle biopsies. To test the association of myofiber regenera-
tion with the amount of a-cardiac–actin positive myofibers,
we studied both female mosaics for dystrophin deficiency
(Fig. 7, D and E) and a series of patient muscle biopsies
from DMD patients (fetal, neonate, 3-, 5-, and 8-yr old),
normal controls, merosin deficiency, and calpain deficiency
(Fig. 7 F). In the manifesting carrier of dystrophin defi-
ciency (Fig. 7, D and E), both dystrophin-positive and dys-
trophin-negative myofibers were strongly positive for
a-cardiac actin, and most appeared to be fully developed
myofibers, suggesting that a-cardiac–actin expression per-
sisted beyond the point of complete myofiber regeneration.
Immunostaining of a-cardiac actin in both normal and
dystrophin-deficient fetal muscle (z18–22-wk gestation)
showed 100% of myofibers to be positive for a-cardiac ac-
tin. By birth, the proportion of a-cardiac–actin positive
myofibers in normal muscle declined to 0%, whereas in
dystrophin-deficient muscle, z60% of fibers remained
strongly positive (Fig. 7 F). This high level was maintained
throughout the disease process. Two unrelated dystrophic
controls, partial merosin deficiency and calpain III defi-
ciency, showed lower levels of a-cardiac actin (z15–20%
positive fibers). As dystrophin-deficient neonatal muscle
shows relatively little evidence of degeneration/regenera-
tion by histopathology, we conclude that the overexpres-
sion of a-cardiac actin shows persistent expression beyond
the normal windows of development and regeneration.
Discussion
Expression Profiling As a Means of Understanding 
Pathological Processes
Here, we report expression profiling as an experimental
approach to define the biochemical cascades underlying
the progressive pathophysiology of the inherited muscular
dystrophies. A critical aspect of expression profiling stud-
ies is to limit the number of variables under study. This be-
comes highly problematic in the study of human pathologi-
Figure 5. Immunolocalization of factor XIIIa shows colocalization with HLA-DR in tissue dendritic cells. (A–C) Immunofluorescent
visualization of factor XIIIa in frozen muscle biopsy sections from DMD (A), a-SGD (B), and normal control (C) are shown. Factor
XIIIa localizes to infiltrating connective tissue cells in both dystrophin- and a-sarcoglycan–deficient muscle; these cells are absent in
control muscle. Double staining of dystrophin-deficient muscle with factor XIIIa (D) and HLA-DR (E) shows colocalization of these
proteins in the majority of cells, suggesting that these are infiltrating dendritic cells. These cells were variably positive for other den-
dritic cell markers, with subsets also positive for CD1a and CD1b in the epimysial connective tissue (dermal dendritic cells), and other
subsets positive for CD14 in the endomysial connective tissue (stationary macrophages) (data not shown). Macrophages infiltrating ne-
crotic fibers were not stained for factor XIIIa (data not shown).Chen et al. Expression Profiling in the Muscular Dystrophies 1331
cal tissue in that there is considerable heterogeneity within
tissue biopsies, differences in the genetic background be-
tween unrelated patients (genetic noise), and many other
uncontrolled variables. One method to control for these
variables is to study large numbers of patient samples, and
then use elaborate statistical analyses to parse specific vari-
ables. This approach requires large numbers of analysis,
which is costly and can be subject to statistical artifacts.
We present a novel approach for expression profiling of
human patient pathological tissues, which we show is suc-
cessful in reducing the effect of many uncontrolled variables
on the resulting data, and thereby uncovering significant
gene expression changes. This method employs tissue biop-
sies from groups of patients with known primary genetic de-
fects that are age matched; the primary biochemical defect
is held constant, and, thus, the major variable under study is
controlled. All sources of experimental variability, includ-
ing genetic background differences and tissue heterogene-
ity, were attenuated through the use of two different regions
of each biopsy and mixing equal amounts of target cRNA
from unrelated patients (Fig. 1). We show that it is critical
to have iterative comparisons of data replicates; z50% of
expression changes identified by one pairwise comparison
were not consistently detected in comparisons of multiple
Figure 6. Versican and thrombospondin IV show upregulation in dystrophin- and a-sarcoglycan–deficient muscle. (A–C) Shown are sec-
tions from dystrophin-deficient (A), a-sarcoglycan–deficient (B), and normal control (C) muscle biopsies immunostained for the large
chondroitin sulfate proteoglycan, versican. Upregulation of versican is seen in the endomysial connective tissue in both dystrophin- and
a-sarcoglycan–deficient muscle. (D–G) Shown are adjacent sections immunostained for thrombospondin IV (D and F), and stained with
hematoxylin and eosin (E and G). A region of grouped necrosis of myofibers is seen in the a-sarcoglycan–deficient muscle (E). This same
region shows a large increase in thrombospondin IV protein production (D). However, in the dystrophin-deficient muscle, regions with
upregulation of thrombospondin IV (F) do not show obvious necrosis in the adjacent sections stained with hematoxylin and eosin (G).The Journal of Cell Biology, Volume 151, 2000 1332
data sets. We showed this iterative method to be accurate in
detecting differentially expressed genes; all differentially
expressed genes tested by protein immunostaining of pa-
tient tissues validated the expression profiling data.
We also present a novel application of expression profil-
ing where two biochemically related primary genetic de-
fects are compared to identify potential members of tran-
scriptional pathways. In this case, patients with primary
genetic defects of two associated proteins, dystrophin
and a-sarcoglycan, were compared; these disorders show
nearly identical clinical, histological, and functional de-
fects. Some of the differentially expressed genes are in-
deed biochemical partners, and our data shows that these
corresponding genes are associated in a transcriptional
regulatory pathway (ERK6, a-syntrophin, and dystro-
phin). Moreover, our data provides the first proof of prin-
ciple that primary genetic defects may be able to be identi-
fied by expression profiling. We found a specific fourfold
decrease in dystrophin RNA in Duchenne dystrophy bi-
opsies. We did not find a similar specific decrease in
a-sarcoglycan gene expression in a-sarcoglycan–deficient
patients, however, this is likely due to the fact that these
patient had missense mutations that typically do not show
nonsense-mediated decay. On the other hand, nearly all
Duchenne dystrophy patients show frameshift mutations
or stop codons that result in nonsense-mediated decay of
the dystrophin mRNA (Hamed et al., 2000).
We provide insights into the disease process of these re-
lated muscular dystrophies at multiple levels: (a) a general
metabolic crisis in patient muscle, (b) novel proteins in-
Figure 7. Developmentally regulated myogenic proteins are persis-
tently upregulated in dystrophin- and a-sarcoglycan–deficient mus-
cle. (A–E) Shown are immunostainings for a-cardiac actin, with
quantitation of the percent of a-cardiac–actin positive myofibers in a
series of muscle biopsies (F). Muscles from patients with dystrophin
deficiency (A), a-SGD (B), normal control (C), and a female mani-
festing carrier for dystrophin deficiency (D) are shown. Immuno-
staining for dystrophin (E) shows mosaic pattern of immunostain-
ing in the female carrier, with both dystrophin-positive and
dystrophin-negative cells. For quantitation, the number of patients
employed is shown on the top of the column at each time point (F).
For each patient, three different fields were counted. The bars indi-
cate the standard deviation derived from three individuals when
three patients were studied, or three fields when only one individual
was included. At the 8–23-yr time point, three 8-yr-old dystrophin-deficiency patients, one 15-yr-old calpain 3–deficiency patient, and
one 23-yr-old merosin-deficiency patient were counted. a-Cardiac actin is developmentally regulated during early muscle development,
but shows little or no expression in normal muscle from birth onwards (C and F). Both show dramatic upregulation in dystrophic mus-
cle, despite little evidence of actively regenerating fibers in the dystrophin deficiency (A) and a-sarcoglycan–deficient (B) muscles. The
a-sarcoglycan–deficient muscle also shows atrophic, angulated fibers (arrows) suggestive of either failed regeneration or denervation;
these fibers are also positive for a-cardiac actin (B). In the female mosaic for dystrophin deficiency, immunostaining for a-cardiac actin
shows both dystrophin-positive and -negative cells to stain positively.Chen et al. Expression Profiling in the Muscular Dystrophies 1333
volved in early stages of myofiber necrosis, (c) novel cells
and proteins involved in local inflammatory and bystander
responses, and (d) persistent expression of developmen-
tally regulated genes suggesting that muscle may assume
a chronically dedifferentiated state. Whereas expression
profiling is widely felt to provide the parallel data genera-
tion needed to understand many complex biological pro-
cesses, previous reports of expression profiling have been
limited to physiological responses of microorganisms to
environmental change and the subclassification of human
cancers (Alon et al., 1999; Golub et al., 1999; Jelinsky and
Samson, 1999). To our knowledge, we present the first re-
port of expression profiling in patient tissues with mono-
genic defects. Below, we briefly discuss some of the more
dramatic changes we identified in the dystrophies, focus-
ing on those that are cell autonomous and those that in-
volve tissue microenvironment (non-cell autonomous).
Many additional interpretations of the data obtained are
possible, however, all data is deposited on a web site
for public access for further analyses (http://microarray.
CNMCResearch.org/resources.htm).
Cell Autonomous Features of the Pathophysiology of 
Dystrophin and a-Sarcoglycan Deficiencies
Many genes involved in mitochondrial function and en-
ergy metabolism were found to be reduced by twofold or
more (26 genes), suggesting generalized mitochondrial
dysfunction and metabolic crisis. Mitochondrial dysfunc-
tion has been reported previously, using a variety of assays
in both human dystrophy patients and animal models, in-
cluding 31P-NMR studies (Barbiroli et al., 1992) and bio-
chemical assays (Gannoun-Zaki et al., 1995; Kuznetsov et
al., 1998). It is widely felt that the chronic calcium influx
due to the poor integrity of the plasma membranes of dys-
trophic muscle leads to calcium overloading of the mito-
chondrial matrix, as well as decreased mitochondrial func-
tion. Our data shows that much of this decreased function
is due to reduced transcription of nuclear-encoded mito-
chondrial genes. The finding of a metabolic defect agrees
with the beneficial effect of performance-enhancing meta-
bolic agents such as creatine, coenzyme Q, carnitine, and
others on dystrophic muscle function (Granchelli et al.,
2000) (J.A. Granchelli, personal communication).
We noted that many important calcium-regulated signal-
ing molecules were downregulated at the transcriptional
level, such as adenylate cyclase (sixfold), calmodulin-depen-
dent protein kinase (fivefold), and phospholipase C (two-
fold). Presumably, this reflects a negative-feedback loop
where the chronic calcium influx from membrane instabil-
ity over stimulates calcium-sensitive pathways, leading to
a compensatory reduction in transcription of the corre-
sponding genes. The downregulation of these genes might
also downregulate down stream protein kinase A and C
that are known to regulate expression of mitochondria
genes and energy metabolism.
We found very high expression of many developmen-
tally regulated genes, including a-cardiac actin (8-fold),
embryonic myosin heavy chain (100-fold), versican (8-
fold), perinatal myosin heavy chain (80-fold), acetylcho-
line receptor a 1 (12-fold), embryonic myosin light chain
(10-fold), and others (Fig. 4). At first, we suspected that
these simply reflected regenerative processes in the mus-
cle, as it is well known that myofiber regeneration recapit-
ulates much of the developmental program of muscle fi-
bers. However, a variety of observations suggested that
expression of these developmentally regulated genes was
not limited to actively regenerating myofibers, and, in-
stead, reflected persistent overexpression of these genes.
First, overexpression of a-cardiac actin was present in 60–
80% of DMD muscle fibers, whereas only a small subset
of these showed histological evidence of regeneration
(Fig. 7). Second, neonatal myofibers from normal muscle
showed no a-cardiac actin, whereas 60–80% of DMD myo-
fibers were positive. Third, mature dystrophin-positive
myofibers in female mosaics also showed high expression
of a-cardiac actin, suggesting that the protein was diffusing
from adjascent dystrophin negative or regenerating re-
gions, or that signals resulting in overexpression were
tramsmitted within mosaic fibers. A previous study of
a-cardiac–actin gene transcription in rat muscle showed
that denervated muscle induced a-cardiac actin mRNA to
levels which were sixfold higher than normal, and, thereaf-
ter, maintained these levels at a constant level (Toyofuko
et al., 1992). Regenerating muscle from an autograft
resulted in mRNA levels that were initially increased by
40-fold, but then dropped to normal levels within 40 d.
Taking these observation together, it is possible that de-
generation/regeneration cycles in dystrophic muscle leads
to high levels of a-cardiac actin mRNA and protein that
diffuse within syncytial myofibers. However, our finding
of the majority of neonatal fibers from preclinical DMD
patient biopsies to be positive for a-cardiac actin suggests
that these may be a persistent overexpression of this pro-
tein in dystrophin-deficient and a-sarcoglycan–deficient
myofibers. We propose a model where this persistent ex-
pression is due to a chronic state of undifferentiation in-
duced by altered Ca21 signaling within the myofiber. Con-
sistent with this model, it has been recently shown that
altering the pattern of Ca21 influx in differentiating myo-
genic cells can determine the developmental pathway that
the cells will take (Naya et al., 2000).
A second result suggesting dedifferentiation of dystro-
phic muscle was the upregulation of versican (eightfold).
Versican is one of the large chondroitin sulfate proteogly-
cans that has been shown to be important during the early
development of muscle (Carrino et al., 1999). Muscle tissue
switches from large proteoglycans, early in development,
to small proteoglycans later. Versican is expressed during
regeneration, but our immunostaining results showed high
level, persistent expression of versican protein throughout
the endomysial connective tissue in both dystrophin defi-
ciency and a-sarcoglycan–deficient muscle, consistent with
the dramatic upregulation of RNA levels shown by the ex-
pression array studies (Fig. 6). Importantly, versican has
been shown to stimulate the proliferation of chondrocytes
(Zhang et al., 1999); we also found upregulation of other
chondrocyte- and bone-related transcripts, such as OSF-2
(4-fold), matrix Gla protein (7-fold), osteopontin (13-fold),
and serine protease 11 (3-fold). Our results suggest that
persistent expression of developmentally regulated genes,
coupled with chronic calcium influx in dystrophin-deficient
myofibers, leads to altered development and regeneration
of myofibers in dystrophic muscles.
The acetylcholine receptor a1 subunit was also dramati-
cally upregulated in patient muscle (19-fold). This protein
is known to increase at extrajunctional sites during bothThe Journal of Cell Biology, Volume 151, 2000 1334
normal development and denervation atrophy (Fischer et
al., 1999), however, similar to a-cardiac actin, the extent of
induction of the acetylcholine receptor seemed too large
to explain by the small amount of regenerating fibers and
the few atrophic fibers seen in the biopsies. Several studies
have demonstrated that deficiency of dystrophin and the
sarcoglycan complex disturb the muscle fiber–laminin in-
teraction and the stability of neuromuscular synapse
(Brown et al., 1999; Grady et al., 2000), and that this leads
to morphological changes of the junction (Zaccaria et al.,
2000). These findings are consistent with two possible
models: either myofibers are in a persistent undifferenti-
ated state, or motor neurons are unable to maintain strong
attachments to myofibers, leading to a constant stimula-
tion of denervation signal pathways.
Non-cell Autonomous Features of the Pathophysiology 
of Dystrophin and a-Sarcoglycan Deficiencies
This is the first report of factor XIIIa1 and HLA-DR1
dendritic cell infiltration in dystrophic muscles. MHC class
II1 dendritic cells have been reported at low level in nor-
mal and regenerating rodent muscles (Pimorady-Esfahani
et al., 1997), and muscle dendritic cells have been shown to
be important in immune aspects of gene delivery to muscle
(Jooss et al., 1998). However, the expression profiling and
immunophenotyping we present here shows that the den-
dritic cell infiltrate in dystrophic muscle is that of activated
dermal dendritic cells. In skin, similar subpopulations of
XIIIa1 and HLA-DR1 dermal dendritic cells have been
shown to be closely associated with tissue mast cells, and in-
creased factor XIIIa protein expression in dendritic cells
has been observed in response to mast cell degranulation
(Sueki et al., 1993). We have shown previously that in mus-
cle, extensive mast cell proliferation and degranulation in
dystrophin-deficient human, dog, and mouse muscle (Gor-
ospe et al., 1994a,b). Also, we have shown that dystrophin-
deficient myofibers are acutely sensitive to mast cell in-
flammatory mediators and proteases, showing widespread
grouped necrosis when exposed to mast cell granules; this is
presumably due to exacerbation of the membrane defect by
the mast cell mediators (Gorospe et al., 1996). Our new re-
sults suggest that dendritic cells and mast cells may act co-
ordinately to mediate chronic and acute microenvironmen-
tal changes in dystrophic muscles. These findings may have
relevance to current treatment of Duchenne dystrophy pa-
tients with steroids. Prednisone is well documented to slow
the progression of DMD and a-SGD, yet the inflammatory
cell target of prednisone has not been identified, as drugs
which inhibit T and B cell function do not seem to benefit
DMD patients (Griggs et al., 1993; Connolly et al., 1998).
Prednisone recently has been shown to prevent activation
of dendritic cells (Matasic et al., 1999). Thus, our findings
suggest that prednisone may improve patient muscle func-
tion by acting on dendritic cell pathways.
We identified a series of novel upregulated proteins in
the endomysial connective tissue of dystrophic muscle that
are traditionally considered developmentally specific iso-
forms, namely thrombospondin IV, SPARC, and versican.
Each of these proteins are also known to be important in
regeneration and/or denervation of muscle. However, we
found that expression of these proteins was not limited to
regions of regenerating myofibers, suggesting that these,
like a-cardiac actin and acetylcholine receptor a1, show a
persistent and/or chronic overexpression in dystrophic
muscle. Importantly, each of these three proteins have
been found to have a role in tissue remodeling and cell mi-
gration; these microenvironmental changes could exacer-
bate the effects of dystrophin deficiency in muscle. The
thrombospondins are a family of extracellular calcium-
binding proteins that are involved in cell proliferation, ad-
hesion, and migration (Arber and Caroni, 1995; Newton et
al., 1999). SPARC/osteonectin is a secreted glycoprotein
that contains modular domains that can function indepen-
dently to bind cells and matrix components. Because
SPARC can selectively disrupt cellular contacts with ma-
trix and, thereby, effect changes in cell shape, it has been
referred to as an anti-adhesin (Lane and Sage, 1994). Ver-
sican is involved in stimulating cell proliferation and mi-
gration in both smooth muscle and chondrocytes (Evanko
et al., 1999; Zhang et al., 1999).
Figure 8. Pathophysiological flow
chart of the muscular dystrophies.Chen et al. Expression Profiling in the Muscular Dystrophies 1335
Conclusion
The global gene expression analyses presented here add
critical new information to existing pathophysiological
models of dystrophin and a-SGD (Fig. 8). Our results sug-
gest that developmental reprogramming, both in the form
of failure to deactivate developmentally regulated genes
and the persistent activation of proteins involved in devel-
opment and regeneration, leads to a series of both cell au-
tonomous, and non-cell autonomous (microenvironmen-
tal) changes. We hypothesize that these changes lead to the
progressive aspects of the human disease and phenotypic
differences in the orthologous animal models. Future ex-
pression profiling experiments will focus on the correlation
of specific pathological cascades with patient age and the
degree of disability, as well as cross-species experiments in
animal models. These will help distinguish between regen-
eration cascades, chronic undifferentiated status, and ab-
normal differentiation pathways in dystrophic muscle.
Our results also show that it is possible to identify pri-
mary genetic defects in patient tissue through analysis of
carefully controlled expression profiling experiments. In
this instance, we were able to show a disease-specific re-
duction of dystrophin mRNA in Duchenne dystrophy
patient muscle (fourfold reduction) compared with a-sar-
coglycan deficient muscle. In the future, molecular diag-
nostics is likely to be possible with expression profile “fin-
gerprints” of patient muscle. These profiles would reflect
both generic responses to pathological processes in muscle
and specific changes reflecting the primary biochemical de-
fect. Critical in the accuracy and sensitivity of such testing
will be the public availability of large numbers of expres-
sion profiles of patients with known genetic defects.
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